Germany's Merck in fresh bid to enter U.S. MS pill market
December 15, 2017 at 05:22 AM EST
FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated its ambitions almost seven years ago.